Henry Schein (HSIC) vs Labcorp (LH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Henry Schein (HSIC) has outperformed Labcorp (LH) over the past year, gaining 28.9% versus a gain of 11.6%. Over five years, LH leads with a +33.7% price change compared with +8.0% for HSIC. Labcorp is the larger company by market cap ($25.20 billion vs $9.24 billion), about 2.7 times the size.
On valuation, Henry Schein trades at a lower forward P/E (13.9x vs 15.7x for Labcorp). Labcorp pays a dividend yielding 0.93%, while Henry Schein does not currently pay one. Labcorp converts more of its revenue into profit, with a net margin of 6.3% versus 3.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HSIC | LH |
|---|---|---|
| Share price | $82.94 | $310.71 |
| Market cap | $9.24B | $25.20B |
| 1-day change | -0.87% | -0.41% |
| YTD return | +10.69% | +24.35% |
| 1-year return | +28.95% | +11.57% |
| 5-year return | +8.03% | +33.70% |
| P/E ratio (TTM) | 24.18 | 25.70 |
| Forward P/E | 13.86 | 15.68 |
| EPS (TTM) | $3.43 | $12.09 |
| Dividend yield | 0.00% | 0.93% |
| Annual dividend | $0.00 | $2.88 |
| Revenue (latest FY) | $13.18B | $13.95B |
| Revenue growth (YoY) | +4.03% | +7.25% |
| Net income (latest FY) | $398.00M | $876.50M |
| Gross margin | 31.14% | 28.76% |
| Operating margin | 4.95% | 9.92% |
| Net margin | 3.02% | 6.28% |
| 52-week high | $92.18 | $341.80 |
| 52-week low | $61.95 | $244.52 |
| Distance from 52-week high | -10.03% | -9.10% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +17.28% | +10.78% |
| Average volume | 1.20M | 737.41K |
| Shares outstanding | 111.45M | 81.10M |
| Employees | 25,000 | 71,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Labcorp is about 2.7 times larger than Henry Schein by market value ($25.20B vs $9.24B).
- HSIC has outperformed LH by 17.4 percentage points over the past year.
About Henry Schein
HSIC stock →Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Health Care · Medical Specialities · 25,000 employees
About Labcorp
LH stock →Labcorp Holdings Inc. provides laboratory services.
Health Care · Medical Specialities · 71,000 employees
HSIC vs LH FAQ
Which is bigger, Henry Schein or Labcorp?
Labcorp (LH) is larger, with a market capitalization of $25.20B compared with $9.24B for Henry Schein (HSIC).
Which stock has performed better over the past year, HSIC or LH?
HSIC returned +28.95% over the past 12 months, compared with +11.57% for LH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HSIC or LH?
HSIC has the lower trailing P/E at 24.2, versus 25.7 for LH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Henry Schein or Labcorp?
Labcorp pays a dividend yielding 0.93%, while Henry Schein does not currently pay a regular dividend.
Are Henry Schein and Labcorp in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.